Fig. 3: Validation of DEGs associated with bortezomib-based treatment responses. | Experimental & Molecular Medicine

Fig. 3: Validation of DEGs associated with bortezomib-based treatment responses.

From: Single-cell analysis of multiple myelomas refines the molecular features of bortezomib treatment responsiveness

Fig. 3

a Dot plots represent the expression levels of 24 genes measured by TLDA. The relative gene expression level was normalized against the endogenous control gene (18S rRNA). Statistical significance was calculated between the OR (n = 54) and SOR (n = 36) groups. The X-axis represents the relative gene expression level (log2 fold changes) based on the mean of the ORs as the calibrator. The detailed results of the 44 selected genes are presented in Supplementary Table 8. *P value < 0.05; **P value < 0.01. b Kaplan–Meier curves for PFS according to the gene expression level. The five genes significantly associated with poor PFS and overall survival in the CoMMpass dataset (SQSTM1, CD320, BCAP31, CCL3, and NPM1) are illustrated. Patients with higher expression (red, >quartile 3) of each gene showed significantly poorer PFS than those with intermediate (green, quartiles 2 and 3) or lower expression (blue, <quartile 1). The detailed data of the 44 selected genes are listed in Supplementary Tables 8 and 9.

Back to article page